AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 38082351 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (MCI) program including education of ICU professionals, identification of patients at risk for agitation, formulation of a multidisciplinary person-centered care plan, and protocolized goal-directed light sedation using dexmedetomidine.
Number of subjects: 480
Study 38082351 — intervention group
Group type: COMPARATOR
Intervention: Standard care with current agitation management protocol including physical restraints.
Number of subjects: 480
Study 38082395 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated newborn care kit (iNCK) provided by Lady Health Workers (LHWs)
Number of subjects: 0
Study 38082395 — intervention group
Group type: COMPARATOR
Intervention: Local standard of care
Number of subjects: 0
Study 38082431 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure-based cognitive behavioral therapy (CBT)
Number of subjects: 40
Study 38082431 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable biosensor (Empatica)
Number of subjects: 40
Study 38082486 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg once daily
Number of subjects: 660
Study 38082486 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 660
Study 38083399 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-aware deep network (CADN) for coronary artery stenosis classification
Number of subjects: 0
Study 38084398 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS (10 consecutive sessions, 20 minutes, 2 mA, two sessions a day over 5 days)
Number of subjects: 34
Study 38084398 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 34
Study 38084398 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 34
Study 38084590 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-moderate hypothermia (20.1-24.0 °C)
Number of subjects: 282
Study 38084590 — intervention group
Group type: COMPARATOR
Intervention: Deep hypothermia (≤20.0 °C)
Number of subjects: 282
Study 38084590 — intervention group
Group type: EXPERIMENTAL
Intervention: High-moderate hypothermia (24.1-28.0 °C)
Number of subjects: 282
Study 38084617 — intervention group
Group type: EXPERIMENTAL
Intervention: 10°C decaffeinated tea
Number of subjects: 30
Study 38084617 — intervention group
Group type: COMPARATOR
Intervention: 50°C decaffeinated tea
Number of subjects: 30
Study 38084725 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g of donor faeces once into the large intestine
Number of subjects: 186
Study 38084725 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g of donor faeces once into the small intestine
Number of subjects: 186
Study 38084725 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 g of donor faeces twice into the small intestine
Number of subjects: 186
Study 38084729 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopist adenoma detection rate (ADR; low or high)
Number of subjects: 16551
Study 38084729 — intervention group
Group type: COMPARATOR
Intervention: PCOL group
Number of subjects: 16551
Study 38084760 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab combined with VRd induction and consolidation therapy and lenalidomide maintenance therapy (D-VRd group)
Number of subjects: 709
Study 38084760 — intervention group
Group type: COMPARATOR
Intervention: VRd induction and consolidation therapy and lenalidomide maintenance therapy alone (VRd group)
Number of subjects: 709
Study 38084760 — intervention group
Group type: EXPERIMENTAL
Intervention: Daratumumab combined with VRd
Number of subjects: 709
Study 38084760 — intervention group
Group type: COMPARATOR
Intervention: VRd
Number of subjects: 709
Study 38084840 — intervention group
Group type: EXPERIMENTAL
Intervention: ginisortamab
Number of subjects: 0
Study 38084850 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual Scale Endoscope (VSE)
Number of subjects: 230
Study 38084850 — intervention group
Group type: COMPARATOR
Intervention: Visual Assessment (VA)
Number of subjects: 230
Study 38084906 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily samples for 10 days
Number of subjects: 101
Study 38084906 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily rapid antigen tests (RATs)
Number of subjects: 101
Study 38084933 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacral neuromodulation (active generator)
Number of subjects: 46
Study 38084933 — intervention group
Group type: COMPARATOR
Intervention: Sacral neuromodulation (inactive generator)
Number of subjects: 46
Study 38084941 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI
Number of subjects: 8796
Study 38084941 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure lowering
Number of subjects: 8796
Study 38084941 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI increase at 1 year
Number of subjects: 8796
Study 38084941 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI and hs-cTnT
Number of subjects: 8796
Study 38085082 — intervention group
Group type: EXPERIMENTAL
Intervention: 4D cardiac CT-derived parameters
Number of subjects: 0
Study 38085172 — intervention group
Group type: EXPERIMENTAL
Intervention: Bempedoic acid
Number of subjects: 0
Study 38085184 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal Estriol
Number of subjects: 0
Study 38085184 — intervention group
Group type: EXPERIMENTAL
Intervention: Microablative Fractional CO2 Laser
Number of subjects: 0
Study 38085214 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsed-field ablation (PFA)
Number of subjects: 65
Study 38085214 — intervention group
Group type: COMPARATOR
Intervention: Radiofrequency ablation (RF)
Number of subjects: 65
Study 38085243 — intervention group
Group type: EXPERIMENTAL
Intervention: AcrySof IQ (SN6AT)
Number of subjects: 58
Study 38085243 — intervention group
Group type: COMPARATOR
Intervention: TECNIS (ZCT/ZMT)
Number of subjects: 58
Study 38085296 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 46
Study 38085296 — intervention group
Group type: EXPERIMENTAL
Intervention: DS107
Number of subjects: 46
Study 38085296 — intervention group
Group type: COMPARATOR
Intervention: All clinical trials
Number of subjects: 46
Study 38085312 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1000 mg orally twice per day from enrollment through delivery
Number of subjects: 831
Study 38085312 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally twice per day from enrollment through delivery
Number of subjects: 831
Study 38085312 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin plus insulin
Number of subjects: 831
Study 38085428 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief intervention (2 individual sessions and 2 phone calls)
Number of subjects: 0
Study 38085428 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention (6 individual sessions and 3 group sessions)
Number of subjects: 0
Study 38085428 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 0
Study 38085470 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal (ID) administration of CoronaVac
Number of subjects: 173
Study 38085470 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular (IM) administration of CoronaVac
Number of subjects: 173
Study 38085556 — intervention group
Group type: EXPERIMENTAL
Intervention: RP4 wearable patch
Number of subjects: 763
Study 38085556 — intervention group
Group type: EXPERIMENTAL
Intervention: DW5 wearable patch
Number of subjects: 763
Study 38085556 — intervention group
Group type: EXPERIMENTAL
Intervention: RW2 wearable patch
Number of subjects: 763
Study 38085559 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum glycated hemoglobin (HbA1c) levels
Number of subjects: 10773
Study 38085559 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher HbA1c levels
Number of subjects: 10773
Study 38085621 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional-equipment RT (TRAD)
Number of subjects: 54
Study 38085621 — intervention group
Group type: COMPARATOR
Intervention: Minimal-equipment RT (MIN)
Number of subjects: 54
Study 38085621 — intervention group
Group type: COMPARATOR
Intervention: Minimal-equipment RT with BFR (MIN + BFR)
Number of subjects: 54
Study 38085710 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital individual Decision Aid (iDA) for cancer screening
Number of subjects: 0
Study 38085798 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal anastomosis (IA)
Number of subjects: 342
Study 38085798 — intervention group
Group type: COMPARATOR
Intervention: Extracorporeal anastomosis (EA)
Number of subjects: 342
Study 38085846 — intervention group
Group type: EXPERIMENTAL
Intervention: Riliprubart 30 mg/kg
Number of subjects: 12
Study 38085846 — intervention group
Group type: EXPERIMENTAL
Intervention: Riliprubart 15 mg/kg
Number of subjects: 12
Study 38085846 — intervention group
Group type: EXPERIMENTAL
Intervention: Riliprubart (both doses)
Number of subjects: 12
Study 38086156 — intervention group
Group type: EXPERIMENTAL
Intervention: Resamirigene bilparvovec (AT132)
Number of subjects: 10
Study 38086377 — intervention group
Group type: EXPERIMENTAL
Intervention: Protein/phosphoprotein-based signatures
Number of subjects: 736
Study 38086377 — intervention group
Group type: EXPERIMENTAL
Intervention: Dichotomous HER2 activation response predictive signature
Number of subjects: 736
Study 38086444 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Coping Skills Training (PCST)
Number of subjects: 640
Study 38086444 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 640
Study 38086444 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (offered to participants taking prescription opioid medications at an average dose of ≥20 morphine milligram equivalents per day)
Number of subjects: 640
Study 38086444 — intervention group
Group type: EXPERIMENTAL
Intervention: PCST and Usual Care (at 24 weeks)
Number of subjects: 640
Study 38086524 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human parathyroid hormone (1-84) (rhPTH[1-84])
Number of subjects: 39
Study 38086585 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety Planning Intervention with structured follow-up (SPI+)
Number of subjects: 0
Study 38086585 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative Assessment and Management of Suicidality (CAMS)
Number of subjects: 0
Study 38086585 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0
Study 38086587 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical hypnosis (MH) and cardiac coherence (CC) training, starting 7 days before surgery.
Number of subjects: 296
Study 38086587 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment to manage preoperative anxiety (Control).
Number of subjects: 296
Study 38086587 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical hypnosis (MH) and cardiac coherence (CC) training.
Number of subjects: 296
Study 38086588 — intervention group
Group type: EXPERIMENTAL
Intervention: Intelligent Hypertension Management System (IHMS) management group (n=160)
Number of subjects: 320
Study 38086588 — intervention group
Group type: COMPARATOR
Intervention: Conventional care group (n=160)
Number of subjects: 320
Study 38086595 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (long-release capsule, doses 18-36-54 mg)
Number of subjects: 0
Study 38086595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisdexamphetamine (LDX, 30-50-70 mg)
Number of subjects: 0
Study 38086595 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 38086910 — intervention group
Group type: EXPERIMENTAL
Intervention: MINOCA patients with an initial normal CMR scan
Number of subjects: 15
Study 38086910 — intervention group
Group type: COMPARATOR
Intervention: Age- and sex-matched volunteers
Number of subjects: 15
Study 38086998 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaradenant 50 mg QD
Number of subjects: 10
Study 38086998 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaradenant 75 mg QD
Number of subjects: 10
Study 38086998 — intervention group
Group type: EXPERIMENTAL
Intervention: Imaradenant (50 mg and 75 mg QD)
Number of subjects: 10
Study 38087071 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothyroidism
Number of subjects: 496
Study 38087071 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated TSH levels
Number of subjects: 496
Study 38087071 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower T3 levels
Number of subjects: 496
Study 38087139 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete Mesocolic Excision (CME)
Number of subjects: 258
Study 38087139 — intervention group
Group type: COMPARATOR
Intervention: Conventional Surgery
Number of subjects: 258
Study 38087258 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary LINC00657
Number of subjects: 36
Study 38087258 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary miR-106a
Number of subjects: 36
Study 38087258 — intervention group
Group type: EXPERIMENTAL
Intervention: Salivary LINC00657 and miR-106a
Number of subjects: 36
Study 38087306 — intervention group
Group type: EXPERIMENTAL
Intervention: RealConsent2.0/alcohol
Number of subjects: 605
Study 38087306 — intervention group
Group type: EXPERIMENTAL
Intervention: RealConsent2.0/placebo
Number of subjects: 605
Study 38087306 — intervention group
Group type: COMPARATOR
Intervention: RealConsent1.0/alcohol
Number of subjects: 605
Study 38087306 — intervention group
Group type: COMPARATOR
Intervention: RealConsent1.0/placebo
Number of subjects: 605
Study 38087306 — intervention group
Group type: COMPARATOR
Intervention: Taking Charge/alcohol
Number of subjects: 605
Study 38087306 — intervention group
Group type: COMPARATOR
Intervention: Taking Charge/placebo
Number of subjects: 605
Study 38087329 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% diquafosol (DQS) eye drops, one drop, six times per day for 8 weeks
Number of subjects: 202
Study 38087329 — intervention group
Group type: COMPARATOR
Intervention: 0.1% hyaluronic acid (HA) eye drops, one drop, six times per day for 8 weeks
Number of subjects: 202
Study 38087393 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical coach employed a standard template to structure coach calls with the NH champion
Number of subjects: 30
Study 38087393 — intervention group
Group type: EXPERIMENTAL
Intervention: Dissemination of materials to family and providers and distribution of tools to staff
Number of subjects: 30
Study 38087393 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation of structured behavioral intervention to improve UTI recognition and management
Number of subjects: 30
Study 38087394 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB + EPO
Number of subjects: 69
Study 38087394 — intervention group
Group type: EXPERIMENTAL
Intervention: UCB
Number of subjects: 69
Study 38087394 — intervention group
Group type: EXPERIMENTAL
Intervention: EPO
Number of subjects: 69
Study 38087394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 38087800 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented femoral stem (Lubinus SP II)
Number of subjects: 61
Study 38087800 — intervention group
Group type: COMPARATOR
Intervention: Uncemented femoral stem
Number of subjects: 61
Study 38087949 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediction model using clinical features (cognitive function assessments, APOE ε4 status, demographics, and brain MRI measures)
Number of subjects: 934
Study 38087967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (BA)
Number of subjects: 0
Study 38087967 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab
Number of subjects: 0
Study 38087967 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa (BA) in NSCLC
Number of subjects: 0
Study 38087967 — intervention group
Group type: COMPARATOR
Intervention: Pembrolizumab in NSCLC
Number of subjects: 0
Study 38088154 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily physical activity measured by wearable smartwatch (Huawei smartwatch)
Number of subjects: 222
Study 38088154 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline step counts within 1 month since discharge
Number of subjects: 222
Study 38088154 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily step counts
Number of subjects: 222
Study 38088156 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard immunosuppression treatment with eltrombopag (Group B)
Number of subjects: 0
Study 38088156 — intervention group
Group type: COMPARATOR
Intervention: Standard immunosuppression treatment (Group A)
Number of subjects: 0
Study 38088422 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-updated ambulatory blood pressure (BP)
Number of subjects: 0
Study 38088422 — intervention group
Group type: COMPARATOR
Intervention: Office systolic blood pressure (SBP)
Number of subjects: 0
Study 38088422 — intervention group
Group type: EXPERIMENTAL
Intervention: Day-time ambulatory SBP
Number of subjects: 0
Study 38088422 — intervention group
Group type: EXPERIMENTAL
Intervention: Night-time ambulatory SBP
Number of subjects: 0
Study 38088422 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean ambulatory SBP
Number of subjects: 0
Study 38088425 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone Replacement Therapy (TRT)
Number of subjects: 100
Study 38088425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 38088463 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnT ESC 0/1-h algorithm in the rule-out zone
Number of subjects: 1422
Study 38088558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziltivekimab 7.5 mg
Number of subjects: 264
Study 38088558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziltivekimab 15 mg
Number of subjects: 264
Study 38088558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziltivekimab 30 mg
Number of subjects: 264
Study 38088558 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 38088558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziltivekimab (all doses)
Number of subjects: 264
Study 38088562 — intervention group
Group type: EXPERIMENTAL
Intervention: B.1.640.1 variant
Number of subjects: 1100
Study 38088562 — intervention group
Group type: EXPERIMENTAL
Intervention: B.1.640.1 Spike
Number of subjects: 1100
Study 38088668 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Serious Illness Care Program (SICP)
Number of subjects: 20
Study 38088765 — intervention group
Group type: EXPERIMENTAL
Intervention: ECPR patients with favorable neurologic outcome
Number of subjects: 97
Study 38088765 — intervention group
Group type: EXPERIMENTAL
Intervention: ECPR patients with ET co2 less than 10 mm Hg
Number of subjects: 97
Study 38088765 — intervention group
Group type: EXPERIMENTAL
Intervention: High-quality CPR
Number of subjects: 97
Study 38088821 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral steroids (prednisolone for 7 to 14 days)
Number of subjects: 2770
Study 38088821 — intervention group
Group type: COMPARATOR
Intervention: Topical (intranasal) steroids (various preparations for 2 weeks to 3 months)
Number of subjects: 2770
Study 38088947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower uric acid (UA) in middle age group
Number of subjects: 36550
Study 38088947 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher uric acid (UA) in middle age group
Number of subjects: 36550
Study 38088947 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower uric acid (UA) in elder age group
Number of subjects: 36550
Study 38088947 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher uric acid (UA) in elder age group
Number of subjects: 36550
Study 38088983 — intervention group
Group type: EXPERIMENTAL
Intervention: RSV-LRTI
Number of subjects: 2094
Study 38088983 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe RSV-LRTI
Number of subjects: 2094
Study 38088983 — intervention group
Group type: EXPERIMENTAL
Intervention: All-cause LRTI
Number of subjects: 2094
Study 38089057 — intervention group
Group type: EXPERIMENTAL
Intervention: Peroral administration of a capsule containing purified DMT and harmine
Number of subjects: 10
Study 38089057 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined administration of an oromucosal harmine tablet and an intranasal DMT spray
Number of subjects: 10
Study 38089061 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplement of standardized dry extracts of amla
Number of subjects: 0
Study 38089167 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard of care treatment
Number of subjects: 312
Study 38089679 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-existing injury complaints (ICPR)
Number of subjects: 320
Study 38089679 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher fitness subjective state
Number of subjects: 320
Study 38089679 — intervention group
Group type: EXPERIMENTAL
Intervention: Illness during the season
Number of subjects: 320
Study 38089924 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 g broccoli sprouts
Number of subjects: 12
Study 38089924 — intervention group
Group type: COMPARATOR
Intervention: Pea sprouts (placebo)
Number of subjects: 12
Study 38090266 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous interferon beta-1a (sc IFN β-1a) treatment
Number of subjects: 577
Study 38090266 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient support programme (PSP)
Number of subjects: 577
Study 38090597 — intervention group
Group type: EXPERIMENTAL
Intervention: SARS-CoV-2 BNT162b2 mRNA vaccination
Number of subjects: 0
Study 38090743 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR at 80% arterial occlusion pressure (AOP)
Number of subjects: 17
Study 38090743 — intervention group
Group type: EXPERIMENTAL
Intervention: BFR at 40% arterial occlusion pressure (AOP)
Number of subjects: 17
Study 38090743 — intervention group
Group type: COMPARATOR
Intervention: Control (no BFR)
Number of subjects: 17
Study 38090880 — intervention group
Group type: EXPERIMENTAL
Intervention: HMP-O2
Number of subjects: 179
Study 38090880 — intervention group
Group type: COMPARATOR
Intervention: SCS
Number of subjects: 179
Study 38090987 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone, 50 mg, twice a day
Number of subjects: 26
Study 38090987 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 38091109 — intervention group
Group type: EXPERIMENTAL
Intervention: ERAS
Number of subjects: 456
Study 38091109 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 456
Study 38091212 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 32
Study 38091212 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 32
Study 38091246 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolvaptan
Number of subjects: 90